Intrathecal Hydromorphone for Chronic Nonmalignant Pain: A Retrospective Study

10.1097/00000542-199209001-01090

10.1001/archneur.56.4.413

10.1023/A:1015994030251

10.1016/S0885-3924(01)00271-8

10.1002/(SICI)1097-0142(19960815)78:4<852::AID-CNCR23>3.0.CO;2-T

10.1016/S0304-3959(97)00018-3

Dickenson, 1991, Mechanisms of the analgesic actions of opiates and opioids, Br Med Bull, 47, 690, 10.1093/oxfordjournals.bmb.a072501

Hill, 1991, Multiple-dose evaluation of intravenous hydromorphone pharmacokinetics in normal human subjects, Anesth Analg, 72, 330, 10.1213/00000539-199103000-00009

10.1016/S0885-3924(99)00036-6

Bruera E Ripamonti C . Alternate routes of administration of opioids for the management of cancer pain. In: Patt R , ed. Cancer Pain. Philadelphia: Lippincott; 1993: 161–184.

10.1097/00006123-199902000-00026

10.1016/S0885-3924(00)00203-7

Fanciullo, 1999, The state of implantable pain therapies in the United States: A nationwide survey of academic teaching programs, Anesth Analg, 88, 1311, 10.1213/00000539-199906000-00021

10.1016/S0885-3924(97)00167-X

10.1097/00006123-199603000-00007

10.1016/S0885-3924(99)00124-4

10.1016/0885-3924(95)00202-2

10.1007/BF03011037

10.1016/S0885-3924(00)00204-9

10.1016/0885-3924(95)00099-2

10.1002/(SICI)1097-0142(19991101)86:9<1856::AID-CNCR30>3.0.CO;2-G

10.1002/(SICI)1097-0142(19980315)82:6<1167::AID-CNCR23>3.0.CO;2-3

10.1046/j.1460-9592.1999.00370.x

10.1111/j.1399-6576.1998.tb05378.x

10.1016/0885-3924(91)90961-3

10.1016/0304-3959(94)90084-1

Houde, 1986, Clinical analgesic studies of hydromorphone, Adv Pain Res Ther, 8, 129

10.1016/0885-3924(93)90118-F

Jacox, 1993, New clinical-practice guidelines for the management of pain in patients with cancer, N Engl J Med, 330, 651, 10.1056/NEJM199403033300926

10.1016/0304-3959(93)90232-E

10.1016/0885-3924(95)90924-C

10.3171/jns.1986.64.6.0890

10.1016/0885-3924(96)00009-7

10.1016/S0885-3924(00)00202-5

Dawson-Saunders B Trapp RG . Basic and Clinical Biostatistics. Norwalk, CT: Appleton-Lange; 1990.

10.1097/00002508-199803000-00003

10.1016/0885-3924(93)90083-8

10.1111/j.1399-6576.1991.tb03237.x

10.1227/00006123-199107000-00013

Coombs, 1982, Intraspinal narcotic tolerance: Preliminary experience with continuous bupivacaine HCl infusion via implanted infusion device, Int J Artif Organs, 5, 379, 10.1177/039139888200500611

10.1016/0304-3959(95)00119-0

10.1016/0304-3959(94)00209-W

10.1016/0304-3959(94)90059-0

10.1111/j.2042-7158.1988.tb05326.x

10.1007/BF01989221

10.1016/0304-3959(89)90100-0

10.1111/j.1600-0773.1989.tb01190.x

Cherny NI Portenoy RK . Practical issues in the management of cancer pain. In: Wall PD Melzack R , eds. Textbook of Pain. New York: Churchill Livingstone; 1999: 1479–1522.

10.1002/bdd.2510140102

Paterson, 1990, Plasma levels of morphine and morphine glucuronides in the treatment of cancer pain: Relationship to renal function and route of administration, Eur J Clin Pharmacol, 38, 121

Cone, 1977, Urinary excretion of hydromorphone and metabolites in humans, rats, dogs, guinea pigs and rabbits, J Pharm Sci, 12, 1709, 10.1002/jps.2600661213

10.1016/0885-3924(94)00121-Z

Abs, 2000, Endocrine consequences of long-term intrathecal administration of opioids, J Clin Endocrinol Metab, 86, 2215, 10.1210/jcem.85.6.6615

10.1016/0885-3924(94)90166-X

10.1016/S0304-3959(97)00059-6

10.1016/S0885-3924(97)00169-3

10.1097/00002508-199609000-00005

10.1016/S0304-3959(99)00101-3

10.1016/0304-3959(89)90194-2